Liu Andrew H, Szefler Stanley J
National Jewish Medical and Research Center, and the University of Colorado Health Sciences Center, Denver, CO, USA.
J Allergy Clin Immunol. 2003 Mar;111(3 Suppl):S785-92. doi: 10.1067/mai.2003.148.
There is significant interest in early identification and intervention in childhood asthma. Current asthma guidelines identify inhaled corticosteroids (ICS) as the preferred initial long-term control therapy even in young children. ICS clearly improve asthma control in children with mild to moderate persistent asthma, but it is not clear that they can alter the natu-ral history and progression of asthma. New insights regarding the origins of asthma and allergy and their natural history will continue to stimulate questions regarding the appropriate time for intervention and will stimulate the design of new treatment strategies and the discovery of new medications.
对儿童哮喘的早期识别和干预存在着浓厚的兴趣。当前的哮喘指南将吸入性糖皮质激素(ICS)确定为首选的初始长期控制疗法,即使是在幼儿中也是如此。ICS能明显改善轻至中度持续性哮喘患儿的哮喘控制情况,但尚不清楚它们能否改变哮喘的自然病史和病程。关于哮喘和过敏的起源及其自然病史的新见解将继续引发有关适当干预时机的问题,并推动新治疗策略的设计和新药物的发现。